Centogene N.V. Stock

Equities

CNTG

NL0014040206

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:45 2024-05-24 pm EDT 5-day change 1st Jan Change
0.374 USD -1.60% Intraday chart for Centogene N.V. +1.08% -68.83%
Sales 2023 48.54M 52.64M Sales 2024 * 59.5M 64.53M Capitalization 9.6M 10.41M
Net income 2023 -35M -37.96M Net income 2024 * -45M -48.8M EV / Sales 2023 0.62 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 0.16 x
P/E ratio 2023
-0.86 x
P/E ratio 2024 *
-0.36 x
Employees 444
Yield 2023 *
-
Yield 2024 *
-
Free-Float 69.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.60%
1 week+1.08%
Current month-10.95%
1 month-22.07%
3 months-59.38%
6 months-68.83%
Current year-68.83%
More quotes
1 week
0.35
Extreme 0.3457
0.40
1 month
0.35
Extreme 0.3457
0.55
Current year
0.35
Extreme 0.3457
1.25
1 year
0.35
Extreme 0.3457
1.98
3 years
0.35
Extreme 0.3457
11.95
5 years
0.35
Extreme 0.3457
28.71
10 years
0.35
Extreme 0.3457
28.71
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 21-12-19
Director of Finance/CFO - 22-02-07
Chief Tech/Sci/R&D Officer 54 15-12-31
Members of the board TitleAgeSince
Chairman 57 20-03-15
Director/Board Member 57 17-06-30
Director/Board Member 68 16-12-31
More insiders
Date Price Change Volume
24-05-24 0.374 -1.60% 53,716
24-05-23 0.3801 -4.26% 99,823
24-05-22 0.397 +3.93% 79,249
24-05-21 0.382 +0.37% 48,755
24-05-20 0.3806 +2.86% 401,791

Delayed Quote Nasdaq, May 24, 2024 at 03:59 pm EDT

More quotes
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3446 EUR
Average target price
1.378 EUR
Spread / Average Target
+299.92%
Consensus